Hi I have terrible written expression skills, but I am good at math. So bear with me through this post and youll be rewarded. Hims & Hers Market Cap: $6.5B Q1 2025 Guidance: HIMS is projecting to grow Revenues at 87% – 94% YoY. This is in the range of $520 million to $540 million. … Read more
Smaller, more easily made drugs that target GLP-1 could treat obesity and diabetes with fewer side effects
A HEALTHCARE worker has insisted Mounjaro has been “life-changing” after she shed five stone in seven months. Connie Bulloch, from Cambuslang, near Glasgow, started using the weight loss jabs in June last year. Connie Bulloch weighed 15st 9lb at her heaviestConnie Bulloch Connie BullochThe healthcare worker is now 10st 7lb[/caption] GettyConnie hails Mounjaro as ‘life-changing’[/caption] … Read more
Are your patients wasting away? Dr Tamaan Osbourne-Roberts explains why lifestyle interventions are a key supplement to GLP-1 agonists for weight management. Medscape
Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, have recently gained attention for their effectiveness in managing weight gain, high blood sugar, and even reducing alcohol cravings. A new clinical … Read more
Drugs like Ozempic, other blood sugar-reducing medications, may stave off dementia.
A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias. Researchers analyzed Medicare data and found that patients taking these drugs had significantly lower rates of cognitive decline compared to those using other glucose-lowering medications.
MillaF/Shutterstock Injectable medications originally developed for the treatment of diabetes are also effective for weight loss, and have surged in popularity for this purpose around the world. In Australia, Ozempic is approved for the treatment of type 2 diabetes, while Wegovy is approved for weight management. Both are formulations of the drug semaglutide, which mimics … Read more
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was trading at $64.49 as of April 15th. NVO’s trailing and forward P/E were 18.76 and 15.41 respectively according to Yahoo Finance. A scientist in a … Read more
